Boston Scientific Corporation (BSX) & Accelerate Diagnostics (AXDX) Head to Head Analysis

Boston Scientific Corporation (NYSE: BSX) and Accelerate Diagnostics (NASDAQ:AXDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.


This table compares Boston Scientific Corporation and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific Corporation 9.04% 23.62% 9.01%
Accelerate Diagnostics -5,062.48% -67.44% -63.75%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Boston Scientific Corporation and Accelerate Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific Corporation 0 4 12 0 2.75
Accelerate Diagnostics 0 0 2 0 3.00

Boston Scientific Corporation presently has a consensus target price of $30.19, indicating a potential upside of 4.29%. Accelerate Diagnostics has a consensus target price of $33.00, indicating a potential upside of 40.13%. Given Accelerate Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Accelerate Diagnostics is more favorable than Boston Scientific Corporation.

Insider & Institutional Ownership

90.5% of Boston Scientific Corporation shares are held by institutional investors. Comparatively, 44.4% of Accelerate Diagnostics shares are held by institutional investors. 0.7% of Boston Scientific Corporation shares are held by insiders. Comparatively, 51.4% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Boston Scientific Corporation has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.

Valuation and Earnings

This table compares Boston Scientific Corporation and Accelerate Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Boston Scientific Corporation $8.71 billion 4.56 $2.31 billion $0.58 49.91
Accelerate Diagnostics $1.29 million 1,009.51 -$61.92 million ($1.23) -19.15

Boston Scientific Corporation has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.


Boston Scientific Corporation beats Accelerate Diagnostics on 8 of the 13 factors compared between the two stocks.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply